Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › topotecan

topotecan

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of topotecan

59 trials tracked of topotecan: 17 in phase 3 or 4 and 14 with published results. The most-cited published study has 1520 citations.

59Trials tracked
17Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 3 17 Phase 2 33 Phase 1 7 Other / NA 2
  1. Phase 3 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed · 1,520 cited
  2. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression Completed · 454 cited
  3. Phase 3 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma Completed · 368 cited
  4. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer Completed · 296 cited
  5. Phase 3 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Completed · 226 cited
  6. Phase 3 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed · 195 cited
Show 44 more trials
  1. Phase 3 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Completed · 183 cited
  2. Phase 3 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma Completed · 130 cited
  3. Phase 3 Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) Completed · 125 cited
  4. Phase 3 Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer Completed · 123 cited
  5. Phase 3 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Completed · 106 cited
  6. Phase 3 Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients Completed · 64 cited
  7. Phase 3 Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer Completed · 45 cited
  8. Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer Completed · 38 cited
  9. Phase 3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed
  10. Phase 3 Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer Completed
  11. Phase 3 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer Completed
  12. Phase 2 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Completed
  13. Phase 2 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer Completed
  14. Phase 2 Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Completed
  15. Phase 2 Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma Completed
  16. Phase 2 Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Completed
  17. Phase 2 Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer Completed
  18. Phase 2 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
  19. Phase 2 Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin Completed
  20. Phase 2 S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed
  21. Phase 2 First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin Completed
  22. Phase 2 M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers Completed
  23. Phase 2 Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) Completed
  24. Phase 2 Therapy for Children With Advanced Stage Neuroblastoma Completed
  25. Phase 2 Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers Completed
  26. Phase 2 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
  27. Phase 2 Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer Completed
  28. Phase 2 Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers Completed
  29. Phase 2 Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed
  30. Phase 2 Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer Completed
  31. Phase 2 Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors Completed
  32. Phase 2 Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer Completed
  33. Phase 2 Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer Completed
  34. Phase 2 Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer Completed
  35. Phase 2 Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Completed
  36. Phase 2 A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed
  37. Phase 2 Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy Completed
  38. Phase 2 Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma Completed
  39. Phase 2 Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer Completed
  40. Phase 2 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Completed
  41. Phase 2 Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer Completed
  42. Phase 2 Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Completed
  43. Phase 2 Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed
  44. Phase 2 BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer Completed

Showing the 50 most-cited and recently-updated of 59 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
B7-H3-targeted ADCs achieve 54% objective response rate in previously treated small cell lung cancer
Allergy & Immunology Meta-analysis
B7-H3-targeted ADCs achieve 54% objective response rate in previously treated small cell lung cancer B7-H3 Targeted Drugs Show Promise for Small Cell Lung Cancer
This systematic review and meta-analysis evaluates B7-H3-targeted antibody-drug conjugates for patients with previously treated small cell l…
New data suggests B7-H3 targeted therapies may offer higher response rates than standard treatments for patients with small cell lung cancer…
Frontiers Aug 13, 2026
Phase II pilot study of hu14.18K322A plus chemotherapy in 153 children with high-risk neuroblastoma
Pediatrics Phase II
Phase II pilot study of hu14.18K322A plus chemotherapy in 153 children with high-risk neuroblastoma New Antibody Boosts Survival in High-Risk Neuroblastoma
This Phase II pilot study enrolled 153 previously untreated children with high-risk neuroblastoma. The study assessed hu14.18K322A combined …
This study shows that combining a new antibody with standard chemotherapy may improve survival rates for children with high-risk neuroblasto…
CT.gov Jun 4, 2026